Braintree Labs. v. Breckenridge Pharm., No. 16-1731 (Fed. Cir. May 5, 2017)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Braintree Laboratories, Inc. (“Braintree”) appeals from the Southern District of New York’s summary judg- ment that Breckenridge Pharmaceutical, Inc. (“Brecke n- ridge”) does not directly infringe or induce infringement of the asserted claims of U.S. Patent No. 6,946,149 (“the ’149 patent”). For the reasons discussed below, we reverse and remand. BACKGROUND The ’149 patent is directed to compositions and met h- ods for purging a patient’s colon, as is routinely performed prior to a colonoscopy.